Biotechnology Transfer & Commercialization Conference
Register 2, the 3rd goes free with the coupon code rcdvb!

Dear Colleague,

Leading innovations in biotech advancement and discovery are found within academic institutions and emerging companies. These organizations play an increasingly important role, both in the U.S. and around the world, in developing new drug therapies for the treatment of diseases ranging from Alzheimer’s to cancer to cystic fibrosis to HIV/AIDS and many others. Their role in researching new therapies is instrumental in developing the next phase of disease treatment.

A gulf exists between early research and commercial drug development. What is considered adequately researched at an academic level is vastly different than what is required on a commercial level. A lack of funding limits the resources many universities are able to devote to advancing new therapies and such efforts are typically beyond their core academic missions. The next steps in drug advancements are both challenging and expensive including advanced clinical trials up to the marketing of successful therapies, requiring significant investments. An era of biotech business paradigm shifts requires a new understanding among the various market segments.

Bridging the gulf requires a dialogue among academic, investment and commercial organizations.

GTC’s Biotechnology Transfer & Commercialization Conference will bring together the players needed to move the industry forward. Leading universities, pharmaceutical companies, venture capital, foundations and biotech companies will come together to share their perspectives, discuss new models of cooperation and develop the business relationships that get deals done. Together they will create new technologies, new companies and new medicines.

This Conference is part of the 8th Modern Drug Discovery and Development Summit. Other conference tracks include:

9th Stem Cell Research and Therapeutics Conference
7th Assay and Drug Discovery Technologies Conference
4th Translational Medicine Conference
3rd Pharmacokinetics and Pharmacodynamics Conference

Best regards,

2012 Biotechnology Transfer & Commercialization Committee

Conference Advisory Board Members:
Patrick Enright, Managing Director, Longitude Capital
Turner Jenkins, Associate, Pappas Ventures
Joel Kirschbaum, Director, UCSF
David Lewin, Senior Associate Director of Licensing, Yale University
Jonathan Lourie, Partner, Edwards Wildman Palmer
Benjamin Martin, Member, Epstein Becker Green
Nina Kjellson, General Partner, InterWest
Christopher K. Mirabelli, HealthcareVentures
Dushyant Pathak, Associate Vice Chancellor, Office of Research, University of California, Davis
Ben Perkins, Group Head, US Life Sciences M&A, Ernst & Young
Keld Sorensen, Senior Manager, Siemens Healthcare Diagnostics

We look forward to seeing you at the conference!

What Past Delegates said:

“Excellent meeting that provided a thorough immersion into the fundamental and leading thoughts in modern drug development. A must for anyone involved in drug discovery/development."
- Santosh Kesari, MD, PhD, Director, UCSD Neuro-oncology.

“The eclectic mix of business leaders and academic scientists highlighted the need for closer attention to the growing role of universities as virtual R&D for not just early stage biotechs but also mid-level life science companies. The importance of training the next generation of scientists in good business practices during their university days was made abundantly clear.”
- Glenn D. Prestwich, PhD, Presidential Professor of Medicinal Chemistry and Director, Entrepreneurial Faculty Scholars, University of Utah

GTC conferences consistently draw high-level and well-known speakers from academia, government and industry to present the most up to date research and developments in the field. Their conferences not only provide excellent food and customer services, but they also select convenient locations that facilitate networking and related-business and recreational activities. I participate in their conferences annually and look forward to the next conference." - Michael D. West, Ph.D., CEO, BioTime, Inc.

“GTC is an excellent conference organizer and is very much a part of our marketing strategy at RBM. We’ve made a commitment to participate in several meetings this year as we’ve found the conferences to be well aligned with our business”
- Robert L Bencher, Director, RBM
Attend ALL GTC Conferences for One Year for only $3,995 ($1,990 for acad/govt).
Click here to sign up!